Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Unknown × nimotuzumab × Clear all

Phase

Phase 2 21 Phase 3 3 Phase NA 2 Phase 4 2 Phase 1/2 2 Phase 2/3 1 Phase 1 1

Status

Completed 2 Withdrawn 1 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Squamous Cell Carcinoma 1

Interventions

Docetaxel 18 Cisplatin 17 Capecitabine 17 Oxaliplatin 14 Drug Therapy 14 Cyclophosphamide 14 Fluorouracil 12 Radiotherapy 11 Paclitaxel 9 apatinib 8 Epirubicin 8 Doxorubicin 8 Decitabine 8 Gemcitabine 7 Carboplatin 7 sintilimab 6 Methotrexate 6 Busulfan 6 camrelizumab 5 anlotinib 5 XELOX 5 Pemetrexed 5 Neoadjuvant Therapy 5 Leucovorin 5 Etoposide 5 Dexamethasone 5 lenvatinib 4 Surgical Procedures, Operative 4 Sorafenib 4 Radiosurgery 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01402180 2011-07-26

Nimotuzumab

Fudan University

Phase 2/3 Unknown

Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡